Overview Financials News + Filings Key Docs Ownership Insiders
|
| In millions, except per share items | Mar-31-23 | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-18 |
| | 10-K | 10-K | 10-K | Source | Source |
| Revenues: |
| United States | 43.4 | 35.3 | 20.9 | | |
| Canada | 8.4 | 12.4 | 13.4 | | |
| Nutraceutical Products | 15.1 | 13.6 | 12.2 | | |
| Processing Services | | | 8.4 | | |
| Total revenues | 51.7 | 47.7 | 34.3 | 0.0 | 0.0 |
| Revenue growth [+] | 8.5% | 39.2% | | | |
| United States | 22.8% | 69.4% | | | |
| Canada | -32.4% | -7.3% | | | |
| Nutraceutical Products | 10.9% | 11.8% | | | |
| Cannabis and Hemp Products | -64.8% | 2370.9% | | | |
| Cost of goods sold [+] | 104.7 | 108.9 | 93.7 | 0.0 | -18.9 |
| Direct costs | 49.6 | 52.6 | | | |
| Gross profit | -52.9 | -61.2 | -59.5 | 0.0 | 18.9 |
| Gross margin | -102.3% | -128.3% | -173.6% | | |
| Selling, general and administrative | -15.2 | | | 64.7 | |
| Other operating expenses | 80.2 | 26.8 | 70.8 | -161.9 | 18.9 |
| EBITDA growth | 34.1% | -32.4% | -234.0% | | |
| EBITDA margin | -228.0% | -184.5% | -380.2% | | |
| Depreciation | -1.7 | -3.4 | -15.1 | | |
| EBITA | -116.3 | -84.6 | -115.1 | 97.2 | 0.0 |
| EBITA margin | -224.8% | -177.4% | -336.1% | | |
| Amortization of intangibles | 1.7 | 3.4 | 15.1 | | |
| EBIT [+] | -118.0 | -88.0 | -130.3 | 97.2 | 0.0 |
| EBIT growth | 34.1% | -32.4% | -234.0% | | |
| EBIT margin | -228.0% | -184.5% | -380.2% | | |
| Non-recurring items [+] | -15.2 | | | 97.2 | |
| Asset impairment | -15.3 | | | | |
| Unusual expense | | | | 97.2 | |
| Interest expense | 0.0 | 0.5 | 0.6 | | |
| Interest expense | 0.0 | 0.5 | 0.6 | | |
| Other income (expense), net [+] | 14.0 | 4.1 | 3.1 | | |
| Gain (loss) on foreign currency transactions | | | | 1.0 | |
| Pre-tax income | -88.8 | -84.4 | -127.7 | 0.0 | 0.0 |
| Income taxes | -28.3 | -9.5 | -3.5 | 0.0 | 0.0 |
| Tax rate | 31.9% | 11.2% | 2.7% | | |
| Net income | -60.5 | -75.0 | -123.2 | -60.9 | 0.0 |
| Net margin | -116.8% | -157.2% | -359.5% | | |
| |
| Basic EPS [+] | ($5.12) | ($15.54) | ($35.55) | ($0.68) | |
| Growth | -67.1% | -56.3% | 5154.7% | | |
| Diluted EPS [+] | ($5.12) | ($15.54) | ($35.55) | ($0.68) | |
| Growth | -67.1% | -56.3% | 5154.7% | | |
| |
| Shares outstanding (basic) [+] | 11.8 | 4.8 | 3.5 | 90.0 | |
| Growth | 144.8% | 39.2% | -96.1% | | |
| Shares outstanding (diluted) [+] | 11.8 | 4.8 | 3.5 | 90.0 | |
| Growth | 144.8% | 39.2% | -96.1% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|